Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal Alphonse DeLucia, MD, Thomas W. Wakefield, MD, Philip C. Andrews, PhD, Brad J. Nichol, BS, Amy M. Kadell, Shirley K. Wrobleski, BS, L.Joe Downing, MD, James C. Stanley, MD Journal of Vascular Surgery Volume 18, Issue 1, Pages 49-60 (July 1993) DOI: 10.1067/mva.1993.42736 Copyright © 1993 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
Fig. 1 Experimental protocol. Journal of Vascular Surgery 1993 18, 49-60DOI: (10.1067/mva.1993.42736) Copyright © 1993 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
Fig. 2 Percent reversal of heparin anticoagulation achieved by variant peptides and n-protamine (protamine [+21P]) as assessed by ACT and heparin anti-factor Xa activity. Journal of Vascular Surgery 1993 18, 49-60DOI: (10.1067/mva.1993.42736) Copyright © 1993 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
Fig. 3 Percent reversal of heparin anticoagulation achieved by variant peptides and n-protamine (Protamine [+21P]) as assessed by TCT and heparin anti-factor IIa activity. Journal of Vascular Surgery 1993 18, 49-60DOI: (10.1067/mva.1993.42736) Copyright © 1993 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
Fig. 4 Mean arterial blood pressure and cardiac output changes observed with variant peptides and n-protamine (Prot.[+21]). Journal of Vascular Surgery 1993 18, 49-60DOI: (10.1067/mva.1993.42736) Copyright © 1993 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions